DelveInsight’s, “Anal Cancer Pipeline Insight 2023” report provides comprehensive insights about 6+ companies and 8+ pipeline drugs in Anal Cancer pipeline landscape. It covers the Anal Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Anal Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Anal Cancer Pipeline Report

• DelveInsight’s Anal Cancer pipeline report depicts a robust space with 6+ active players working to develop 8+ pipeline therapies for Anal Cancer treatment.
• The leading companies working in the Anal Cancer Market include Incyte Corporation, Merck & Co, Novartis Pharmaceuticals, Advaxis, Merck KGaA, and others.
• Promising Anal Cancer Pipeline Therapies in the various stages of development include Pembrolizumab, MPDL3280A, mDCF, BMX-001, TP-1454 monotherapy, Axalimogene filolisbac, cisplatin, fluorouracil, and others.
• November 2023: Sumitomo Pharma America Inc. announced a study of Phase 1 clinical trials for TP-1454 monotherapy. This study will evaluate the safety and tolerability of oral TP-1454 in patients with advanced metastatic or progressive solid tumors and anal cancer.
• November 2023: Merck Sharpy & Dohme LLC announced a study of Phase 2 clinical trials for Pembrolizumab. In this study, participants with multiple types of advanced (unresectable and/or metastatic) solid tumors who have progressed on standard of care therapy will be treated with pembrolizumab (MK-3475).
• November 2023: Novartis Pharmaceuticals announced a study of Phase 1 clinical trials for KFA115 and tislelizumab. The purpose of this study is to characterize the safety and tolerability of KFA115 and KFA115 in combination with tislelizumab in patients with select advanced cancers, and to identify the maximum tolerated dose and/or recommended dose.
• November 2023: Shattuck Labs Inc. announced a study of Phase 1 clinical trials for SL-279252. This is a Phase 1 first in human, open label, multi-center, dose escalation and dose expansion study to evaluate the safety, tolerability, PK, anti-tumor activity and pharmacodynamic effects of SL-279252 in subjects with advanced solid tumors or lymphomas.
• November 2023: LegoChem Biosciences Inc. announced a study of Phase 1 & 2 clinical trials for LCB84. The study population in dose escalation (Phase 1) consists of patients with advanced solid tumors refractory to standard of care, or for whom no standard of care exists. After the MTD and/or RP2D for single agent LCB84 is determined, dose escalation cohorts with select tumor types will be enrolled. Combination LCB84 and anti-PD-1 Ab will be evaluated in dose escalation after a minimum of 2 dose levels of single agent LCB84 have established DLT safety, to determine the MTD and/or RP2D of combination LCB84 and anti-PD-1 Ab, and to continue into dose expansion cohorts in select tumor types.

 

Request a sample and discover the recent advances in Anal Cancer Treatment Drugs @ Anal Cancer Pipeline Report

 

In the Anal Cancer pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Anal Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Anal Cancer Overview

Anal cancer is a rare condition, although its incidence has been increasing over the past several decades, particularly in women. The majority of anal cancers are squamous cell cancers and are linked with human papillomavirus (HPV) infection. There is a clear correlation between human papillomavirus (HPV) infection, mainly HPV 16, and anal cancer. Hence, there is an increased incidence in certain populations, such as young men who have genital viral infections.

 

Find out more about Anal Cancer Therapeutics Assessment @ Anal Cancer Preclinical and Discovery Stage Products

 

Anal Cancer Emerging Drugs Profile

• PDS0101: Merck & Co
• Avelumab: Merck KGaA

 

Anal Cancer Pipeline Therapeutics Assessment

There are approx. 6+ key companies which are developing the therapies for Anal Cancer. The Anal Cancer companies which have their Anal Cancer drug candidates in the most advanced stage, i.e. phase II include, Merck & Co.

 

DelveInsight’s Anal Cancer pipeline report covers around 8+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

 

Anal Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

 

Anal Cancer Pipeline Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

 

Learn more about the emerging Anal Cancer Pipeline Therapies @ Anal Cancer Clinical Trials Assessment

 

Scope of the Anal Cancer Pipeline Report

• Coverage- Global
• Anal Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Anal Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Anal Cancer Companies- Incyte Corporation, Merck & Co, Novartis Pharmaceuticals, Advaxis, Merck KGaA, and others.
• Anal Cancer Pipeline Therapies- Pembrolizumab, MPDL3280A, mDCF, BMX-001, TP-1454 monotherapy, Axalimogene filolisbac, cisplatin, fluorouracil, and others.

 

Dive deep into rich insights for new drugs for Anal Cancer Treatment, Visit @ Anal Cancer Market Drivers and Barriers, and Future Perspective

 

Table of Content

1. Introduction
2. Executive Summary
3. Anal Cancer: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Anal Cancer– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Retifanlimab: Incyte Corporation
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. PDS0101: Merck & Co
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. Drug Name: Company Name
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug name: Company name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Anal Cancer Key Companies
21. Anal Cancer Key Products
22. Anal Cancer- Unmet Needs
23. Anal Cancer- Market Drivers and Barriers
24. Anal Cancer- Future Perspectives and Conclusion
25. Anal Cancer Analyst Views
26. Anal Cancer Key Companies
27. Appendix

 

For further information on the Anal Cancer Pipeline therapeutics, reach out to Anal Cancer Unmet Needs and Analyst Views

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/parkinsons-disease-market-size-analysis-treatment